[{"id":"36e9c4c3-28f9-471f-91db-41aa4b6178a4","acronym":"RAINBO","url":"https://clinicaltrials.gov/study/NCT05255653","created_at":"2022-02-24T13:52:52.644Z","updated_at":"2025-02-25T15:00:17.741Z","phase":"Phase 2/3","brief_title":"Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features","source_id_and_acronym":"NCT05255653 - RAINBO","lead_sponsor":"Leiden University Medical Center","biomarkers":" ER • POLE","pipe":" | ","alterations":" ER positive • MSI-H/dMMR • POLE mutation","tags":["ER • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • MSI-H/dMMR • POLE mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • megestrol • medroxyprogesterone"],"overall_status":"Recruiting","enrollment":" Enrollment 1615","initiation":"Initiation: 11/11/2021","start_date":" 11/11/2021","primary_txt":" Primary completion: 01/01/2030","primary_completion_date":" 01/01/2030","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2024-11-28"}]